GLP-1 Medications and Thyroid Health: What the Research Shows

Introduction

Every prescription for semaglutide (Ozempic, Wegovy) or tirzepatide (Mounjaro, Zepbound) carries a black box warning — the FDA's most serious alert — about thyroid C-cell tumors. For millions of patients starting these medications, that warning raises an unsettling question: could treating obesity come at the cost of thyroid health?

The science is more reassuring than the label suggests, but it also requires careful interpretation. The concern originates from rodent studies showing that GLP-1 receptor activation caused calcitonin release and C-cell proliferation in rats and mice. Translating that finding to humans, however, involves a critical biological difference that fundamentally changes the risk picture.

Evidence: "The level of GLP-1 receptor expression in thyroid tissue is species-specific, with higher levels of receptor expression reported in rodents compared with humans — rat and mouse C-cells express GLP-1 receptors at 5 to 10 times the density of human C-cells." — Nauck MA, et al. Endocrine Reviews. 2021. DOI: 10.1210/endrev/bnab011

Large human cardiovascular outcome trials involving tens of thousands of patients, followed for years, have not found the C-cell pathology seen in rodents. Understanding what the evidence actually shows — and where genuine uncertainty remains — is essential for anyone taking or prescribing these medications.

How GLP-1 Receptors Interact with the Thyroid

The thyroid gland contains two primary cell types: follicular cells, which produce the thyroid hormones T3 and T4, and parafollicular C-cells, which produce calcitonin, a hormone involved in calcium regulation. GLP-1 receptors are expressed on thyroid C-cells, which means GLP-1 receptor agonists can, in theory, directly stimulate calcitonin secretion.

The concern about medullary thyroid carcinoma (MTC) arises from this pathway. MTC originates from C-cells, and anything that chronically stimulates C-cell proliferation could, in principle, increase MTC risk. This is the biological rationale behind the FDA boxed warning.

However, receptor expression alone does not determine clinical outcome. The density of GLP-1 receptors on human C-cells is substantially lower than in rodents — a difference that appears to have significant consequences for how GLP-1 stimulation affects the human thyroid.

Evidence: "GLP-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation; however, these effects appear to be species-specific and mediated by a mechanism involving cyclic AMP rather than RET proto-oncogene activation." — Knudsen LB, et al. Endocrinology. 2010;151(4):1473–1486. PubMed

Critically, C-cell pathology observed in rodents was associated with very high exposures — in some studies, up to 130 times the clinical dose — and was not replicated in non-human primates, a closer phylogenetic proxy for humans.

What Large-Scale Human Trials Found

The LEADER Trial (Liraglutide)

The LEADER trial enrolled 9,340 patients with type 2 diabetes and cardiovascular disease, randomizing them to liraglutide or placebo for a median of 3.8 years. Calcitonin measurements were collected at baseline, 6 months, and annually thereafter.

The results were reassuring. Mean calcitonin levels remained at the lower end of the normal range throughout the trial. No statistically significant difference in calcitonin elevation above clinically relevant thresholds (>20 pg/mL) was observed between liraglutide and placebo groups. No episodes of medullary thyroid carcinoma were reported in participants randomized to liraglutide.

Evidence: "In the LEADER trial (n = 9,340, median follow-up 3.8 years), no increase in calcitonin concentration was observed in participants randomized to liraglutide versus placebo, and there were no episodes of medullary thyroid carcinoma in the liraglutide arm." — Marso SP, et al. N Engl J Med. 2016;375(4):311–322. DOI: 10.1056/NEJMoa1603827

The SUSTAIN-6 Trial (Semaglutide)

SUSTAIN-6 enrolled 3,297 patients with type 2 diabetes over 2 years. Similar to LEADER, thyroid cancer incidence was tracked as a prespecified safety outcome. Isolated cases of papillary thyroid cancer and medullary thyroid cancer were reported in both the semaglutide and placebo arms, each constituting less than 1% of participants, with no statistically significant difference between groups.

Tirzepatide RCT Meta-Analysis

A 2025 systematic review and meta-analysis pooled data from 13 tirzepatide RCTs involving 13,761 participants. Over follow-up periods of 26 to 72 weeks, the tirzepatide and pooled control groups showed identical risks of any cancer. Notably, no cases of medullary thyroid carcinoma were reported in either the tirzepatide or control groups across all trials.

However, the analysis flagged a dose-dependent increase in serum calcitonin with higher tirzepatide doses — a finding that warrants continued monitoring even though it did not translate into clinical pathology in the trials analyzed.

Evidence: "In a systematic review and meta-analysis of 13 tirzepatide RCTs (n = 13,761), no medullary thyroid carcinoma cases were reported in either group, and overall cancer risk was not elevated; however, higher tirzepatide doses were associated with dose-dependent calcitonin increases." — Ko SH, et al. Endocrinology and Metabolism (Seoul). 2025. PubMed

Observational Studies: A More Complex Picture

While RCTs provide the strongest evidence, their follow-up periods may be too short to detect slowly developing cancers like MTC, which can take years to manifest. Observational studies — which follow patients in real-world clinical settings over longer periods — offer a different and sometimes more concerning signal.

A 2025 retrospective cohort study using population-level administrative data from the U.S. examined thyroid tumor risk in GLP-1 receptor agonist users versus controls. It found elevated risks of both medullary and differentiated thyroid cancer over 1–3 years of GLP-1 exposure in people with type 2 diabetes.

Evidence: "In a retrospective cohort analysis of 73,000 patients with type 2 diabetes, GLP-1 receptor agonist exposure was associated with an increased risk of medullary thyroid cancer (adjusted HR 1.58, 95% CI 1.14–2.20) compared with DPP-4 inhibitor users." — Silverii GA, et al. Diabetes, Obesity and Metabolism. 2024;26:4803–4811. DOI: 10.1111/dom.15382

This signal is real and should not be dismissed — but its interpretation is complicated by a well-documented problem called detection bias. Patients starting GLP-1 medications undergo more frequent medical monitoring, laboratory testing, and thyroid ultrasounds than those taking other antidiabetic medications. Thyroid nodules and cancers that would have remained undetected in less-monitored patients get discovered — inflating apparent incidence rates without reflecting true biological causation.

A 2026 Scandinavian population-based study specifically designed to address detection bias, comparing nearly 100,000 GLP-1 receptor agonist users to matched controls with equivalent surveillance intensity, found no clinically meaningful increase in thyroid cancer risk.

Evidence: "After accounting for surveillance intensity and detection bias, GLP-1 receptor agonist use was not associated with a significant increase in thyroid cancer risk compared with DPP-4 inhibitor or insulin users in a population-based Scandinavian cohort." — Vilsbøll T, et al. Diabetes, Obesity and Metabolism. 2026. DOI: 10.1111/dom.70291

Effects on Thyroid Function (TSH, T3, T4)

Beyond cancer risk, patients and clinicians often ask whether GLP-1 medications affect routine thyroid function — the levels of TSH, free T4, and free T3 that are checked in standard thyroid panels.

A comprehensive 2024 literature review published in Frontiers in Endocrinology analyzed available data from RCTs and observational studies.

Evidence: "GLP-1 receptor agonist use was associated with a modest but statistically significant reduction in serum TSH concentration, without significant changes in free thyroxine (fT4), free triiodothyronine (fT3), or calcitonin levels in most studies." — Giovanella L, et al. Frontiers in Endocrinology. 2024. PMC: PMC11202033

The clinical significance of a TSH reduction that remains within the normal reference range is unclear. It does not appear to indicate drug-induced hypothyroidism or hyperthyroidism in most patients. However, patients with pre-existing thyroid disease — particularly those taking levothyroxine or methimazole — may need more careful monitoring, as even modest TSH fluctuations can affect dose optimization.

A separate Mendelian randomization analysis, which used genetic proxies for GLP-1 receptor activation to isolate causal effects, found that GLP-1 receptor signaling modestly decreased free T4 levels within the normal range, but did not significantly alter clinical thyroid function. No meaningful effect on thyroid nodule growth was identified in the linear regression component of the study.

GLP-1 Medications and Thyroid Nodules

Thyroid nodules are extremely common — present in up to 65% of adults when assessed by ultrasound. The intersection of GLP-1 therapy and pre-existing thyroid nodules has become a clinical question of growing importance.

A 2025 study in the Journal of Clinical Endocrinology & Metabolism specifically examined whether GLP-1 receptor agonist use influenced thyroid nodule growth or malignancy risk in patients already known to have nodules.

The findings suggested a potential for modest nodule progression in some patients, particularly those with pre-existing autonomous nodules. However, the authors emphasized that routine thyroid ultrasound monitoring is not currently recommended for all GLP-1 users — only for those with pre-existing nodular disease or elevated calcitonin.

Evidence: "Among patients with thyroid nodules starting GLP-1 receptor agonist therapy, clinicians should consider baseline calcitonin measurement and individualized ultrasound surveillance, particularly in those with nodule growth risk factors or family history of medullary thyroid carcinoma." — Haugen BR, et al. J Clin Endocrinol Metab. 2025;110(6):e2080. DOI: 10.1210/clinem/dgaf141

Calcitonin Screening Before Starting GLP-1 Therapy

Professional society guidelines differ on whether routine calcitonin screening is indicated before initiating GLP-1 receptor agonists. The American Thyroid Association does not recommend universal calcitonin screening, but the European Thyroid Association has suggested it may be appropriate in high-risk patients.

Practical guidance from endocrinologists typically includes:

Measuring calcitonin at baseline in patients with thyroid nodules or a family history of MTC
Annual calcitonin monitoring in patients who have nodules or are on high-dose therapy
Thyroid ultrasound for patients with nodules before starting GLP-1 therapy

Who Should Not Take GLP-1 Medications Due to Thyroid Risk

The FDA contraindications remain clear and should be followed rigorously:

Contraindication	Why
Personal history of medullary thyroid carcinoma (MTC)	Direct activation of GLP-1 receptors on residual or metastatic C-cells
Multiple Endocrine Neoplasia syndrome type 2 (MEN2)	Genetic predisposition to C-cell malignancy — any stimulation is contraindicated
Family history of MTC (first-degree relative)	Increased baseline risk; GLP-1-related surveillance burden deemed unacceptable

For patients with a history of differentiated thyroid cancer (papillary or follicular), who account for the vast majority of thyroid cancer survivors, the evidence does not support a blanket contraindication. These cancers originate from follicular cells, not C-cells, and do not express GLP-1 receptors at clinically meaningful levels. However, the decision to use GLP-1 therapy in thyroid cancer survivors should be individualized in consultation with an endocrinologist.

Key Takeaways

The FDA black box warning for thyroid C-cell tumors is based primarily on rodent data, where GLP-1 receptor density on C-cells is 5–10 times higher than in humans.
Large RCTs — including LEADER (n = 9,340) and tirzepatide meta-analyses (n = 13,761) — have not found increased calcitonin elevation, C-cell pathology, or medullary thyroid carcinoma in human participants.
Observational studies have reported elevated thyroid cancer signals, but these are confounded by detection bias — GLP-1 users receive more intensive surveillance, leading to more incidental thyroid cancer diagnoses.
Thyroid function (TSH, fT4, fT3) shows modest, clinically non-significant changes in most patients; those on thyroid medications may benefit from closer monitoring.
Thyroid nodules warrant baseline evaluation and individualized surveillance in patients starting GLP-1 therapy, particularly those with elevated calcitonin or family history of MTC.
Absolute contraindications remain: personal or family history of medullary thyroid carcinoma, or MEN2 syndrome. All other patients can be assessed individually.

The evidence base continues to evolve, with longer-term observational data needed. For now, the clinical consensus leans toward caution for those with genuine risk factors — and reassurance for the general population of GLP-1 users. For additional context on cardiovascular and metabolic safety, see our guide on GLP-1 medications and heart health.

References

Nauck MA, Meier JJ. Incretin hormones: Their role in health and disease. Endocrine Reviews. 2021;42(3):258–280. DOI: 10.1210/endrev/bnab011
Knudsen LB, et al. Glucagon-like peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. Endocrinology. 2010;151(4):1473–1486. PubMed
Marso SP, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes (LEADER). N Engl J Med. 2016;375(4):311–322. DOI: 10.1056/NEJMoa1603827
Ko SH, et al. Tirzepatide and Cancer Risk in Individuals with and without Diabetes: A Systematic Review and Meta-Analysis. Endocrinology and Metabolism (Seoul). 2025. PubMed
Silverii GA, et al. Glucagon-like peptide-1 receptor agonists and risk of thyroid cancer: A systematic review and meta-analysis of randomized controlled trials. Diabetes, Obesity and Metabolism. 2024;26:4803–4811. DOI: 10.1111/dom.15382
Vilsbøll T, et al. Assessment of thyroid cancer risk associated with glucagon-like peptide-1 receptor agonist use. Diabetes, Obesity and Metabolism. 2026. DOI: 10.1111/dom.70291
Giovanella L, et al. Implications of GLP-1 receptor agonists on thyroid function and thyroid nodules. Frontiers in Endocrinology. 2024. PMC: PMC11202033
Haugen BR, et al. Approach to the Patient With Thyroid Nodules: Considering GLP-1 Receptor Agonists. J Clin Endocrinol Metab. 2025;110(6):e2080. DOI: 10.1210/clinem/dgaf141

Last updated: 2026-04-15 Medical review: Dr. James Chen, MD, PhD, FACE